dimethyl-fumarate-nrf2-ad-nct06850597

Dimethyl Fumarate Phase 2 - Nrf2 Activation for Alzheimer's Disease (NCT06850597)

Overview

This Phase 2 clinical trial investigates dimethyl fumarate (DMF), an established multiple sclerosis drug with potent Nrf2-activating properties, as a potential disease-modifying treatment for Alzheimer's disease. The trial represents a drug repurposing approach, taking advantage of the well-characterized safety profile of DMF (marketed as Tecfidera for multiple sclerosis) to target neuroprotective pathways via Nrf2 transcription factor activation in AD[@nct].

The study addresses a critical gap in AD therapeutics by targeting the oxidative stress and neuroinflammation components of the disease that are not addressed by current amyloid-targeting approaches. Oxidative stress is one of the earliest detectable pathological features in AD, and the Nrf2 pathway is the cell's primary defense mechanism against oxidative damage[@nrf22023].

Alzheimer's disease (AD) is the most common cause of dementia, affecting approximately 6.5 million Americans and 55 million people worldwide. The disease is characterized by progressive cognitive decline, with memory loss being the most prominent early symptom. Despite extensive research, no cure exists, and current treatments provide only modest symptomatic benefit. This has driven interest in drug repurposing—identifying existing drugs with mechanisms that may address AD pathology.

Dimethyl Fumarate Phase 2 - Nrf2 Activation for Alzheimer's Disease (NCT06850597)

Overview

This Phase 2 clinical trial investigates dimethyl fumarate (DMF), an established multiple sclerosis drug with potent Nrf2-activating properties, as a potential disease-modifying treatment for Alzheimer's disease. The trial represents a drug repurposing approach, taking advantage of the well-characterized safety profile of DMF (marketed as Tecfidera for multiple sclerosis) to target neuroprotective pathways via Nrf2 transcription factor activation in AD[@nct].

The study addresses a critical gap in AD therapeutics by targeting the oxidative stress and neuroinflammation components of the disease that are not addressed by current amyloid-targeting approaches. Oxidative stress is one of the earliest detectable pathological features in AD, and the Nrf2 pathway is the cell's primary defense mechanism against oxidative damage[@nrf22023].

Alzheimer's disease (AD) is the most common cause of dementia, affecting approximately 6.5 million Americans and 55 million people worldwide. The disease is characterized by progressive cognitive decline, with memory loss being the most prominent early symptom. Despite extensive research, no cure exists, and current treatments provide only modest symptomatic benefit. This has driven interest in drug repurposing—identifying existing drugs with mechanisms that may address AD pathology.

Dimethyl fumarate represents a compelling candidate for repurposing due to its established safety profile in multiple sclerosis, its ability to activate the Nrf2 pathway (which is dysregulated in AD), and its anti-inflammatory properties. The Medical University of Lodz in Poland is conducting this Phase 2 trial to evaluate whether DMF can slow cognitive decline in patients with mild-to-moderate AD.

Pathway / Mechanism Diagram

Oxidative Stress in Alzheimer's Disease

Role of Oxidative Damage

Oxidative stress is recognized as a central pathological feature of Alzheimer's disease, with evidence of oxidative damage present even in early disease stages. The brain is particularly vulnerable to oxidative damage due to:

• High oxygen consumption (20% of body oxygen despite 2% of body weight)
• High lipid content (DHA, which is highly susceptible to peroxidation)
• Limited antioxidant capacity compared to other organs
• High mitochondrial density generating reactive oxygen species (ROS)

Mitochondrial Dysfunction:

• Electron transport chain complexes I and IV show reduced activity
• Increased mitochondrial DNA mutations in AD brain
• Impaired calcium buffering leads to ROS generation
• Mitochondrial permeability transition pore opening

• Iron, copper, and zinc accumulate in AD brain
• Transition metals catalyze Fenton reactions generating hydroxyl radicals
• Amyloid-beta interacts with metals, promoting oxidation

• Activated microglia produce ROS and reactive nitrogen species
• NADPH oxidase activation in glial cells
• Cytokine-induced oxidative burst

• Glucose oxidation products accumulate in AD brain
• AGEs cross-link proteins, forming age pigment
• RAGE receptor engagement promotes inflammation

Evidence of Oxidative Damage in AD

Multiple biomarkers demonstrate oxidative stress in AD:

| Biomarker | Change in AD | Source |
|-----------|--------------|--------|
| 8-OHdG (DNA oxidation) | Increased | Brain tissue, CSF, urine |
| 4-HNE (lipid peroxidation) | Increased | Brain tissue, plasma |
| 8-iso-PGF2α (lipid peroxidation) | Increased | Plasma, urine |
| Protein carbonyls | Increased | Brain tissue, plasma |
| GSH/GSSG ratio | Decreased | Brain tissue, CSF |
| SOD activity | Variable | Brain tissue |

This oxidative damage correlates with cognitive decline and disease severity, making antioxidant pathways attractive therapeutic targets.

The Nrf2 Pathway

Nrf2 Biology

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator of cellular defense against oxidative stress. This transcription factor controls the expression of over 200 genes involved in antioxidant responses, xenobiotic metabolism, and cellular protection.

Nrf2 Structure and Function:
Nrf2 is a basic leucine zipper transcription factor encoded by the NFE2L2 gene. It contains seven highly conserved domains (Neh1-7), each with distinct functions:

• Neh1: DNA binding and dimerization with small Maf proteins
• Neh2: Transactivation domain containing Keap1 interaction sites
• Neh3-6: Transactivation domains
• Neh7: Interaction with other transcription factors

Activation Mechanism:

Nrf2 Target Genes

Nrf2 regulates a comprehensive network of protective genes:

Phase 2 Detoxification Enzymes:

• NAD(P)H:quinone oxidoreductase 1 (NQO1)
• Glutamate-cysteine ligase (GCL) - rate-limiting step in GSH synthesis
• Glutathione S-transferases (GSTs)
• UDP-glucuronosyltransferases (UGTs)
• Sulfotransferases (SULTs)

• Heme oxygenase-1 (HO-1)
• Thioredoxin (Trx)
• Thioredoxin reductase (TrxR)
• Peroxiredoxins (Prxs)
• Superoxide dismutases (SOD1, SOD2, SOD3)

• Multidrug resistance-associated proteins (MRPs)
• Aldehyde dehydrogenases (ALDHs)
• Autophagy proteins (p62/SQSTM1)

Nrf2 Dysfunction in AD

Multiple mechanisms contribute to Nrf2 impairment in AD:

Transcriptional Dysregulation:

• Nrf2 nuclear translocation is reduced in AD brain
• ARE-binding activity is diminished
• Epigenetic silencing of NFE2L2 has been reported

• Oxidative modifications of Keap1 in AD may dysregulate its function
• p62 accumulation (common in AD) may sequester Keap1

• Proteasomal degradation of Nrf2 may be enhanced
• Nuclear export may be increased

Mechanism of Action

Nrf2-ARE Pathway Activation

Dimethyl fumarate (DMF) exerts its neuroprotective effects primarily through Nrf2 pathway activation:

The resulting gene expression changes include:

| Gene | Function | Benefit in AD |
|------|----------|----------------|
| NQO1 | Coenzyme Q10 regeneration | Mitochondrial protection |
| HO-1 | Heme degradation, anti-inflammatory | Neuroprotection |
| GCLM | Glutathione synthesis | Antioxidant capacity |
| SOD2 | Superoxide dismutase | Mitochondrial ROS scavenging |
| PRDX1 | Peroxide reduction | Oxidative stress reduction |
| NQO1 | Coenzyme Q10 regeneration | Energy metabolism |

Anti-inflammatory Effects

Beyond direct antioxidant effects, Nrf2 activation suppresses neuroinflammation:

• Cytokine Suppression: Nrf2 inhibits NF-κB signaling, reducing IL-1β, TNF-α, IL-6
• Microglial Modulation: Nrf2 promotes anti-inflammatory microglial phenotype
• Inflammasome Inhibition: Nrf2 activation reduces NLRP3 inflammasome activation
• T-cell Regulation: Nrf2 modulates adaptive immune responses

Amyloid Beta Modulation

Preclinical evidence suggests DMF may affect amyloid pathology:

• Reduced Aβ-induced oxidative stress
• Decreased amyloid precursor protein processing
• Enhanced clearance of Aβ aggregates
• Protection against Aβ-induced neurotoxicity

Mitochondrial Protection

Nrf2 activation protects mitochondria through:

• Enhanced expression of mitochondrial antioxidants (SOD2, Prx3, Trx2)
• Improved mitochondrial biogenesis (via PGC-1α cooperation)
• Protection against mitochondrial permeability transition
• Enhanced mitophagy

Rationale for Repurposing

Multiple Sclerosis Clinical Experience

Dimethyl fumarate (Tecfidera) received FDA approval for relapsing-remitting multiple sclerosis (RRMS) in 2013, providing extensive clinical experience:

Efficacy:

• Reduced annualized relapse rate by 46% vs. placebo in DEFINE trial
• Reduced disability progression by 38% vs. placebo
• Significant reduction in MRI lesions

• Well-characterized adverse event profile
• Common events: flushing, gastrointestinal symptoms, lymphopenia
• Rare serious events: progressive multifocal leukoencephalopathy (PML), severe liver injury
• No increased malignancy risk with extended follow-up

• Oral bioavailability
• CNS penetration demonstrated
• Metabolized to monomethyl fumarate (active metabolite)
• Twice-daily dosing

AD-Specific Rationale

Alzheimer's disease shares pathological features with multiple sclerosis that DMF may address:

• Oxidative Stress: Prominent in both conditions
• Neuroinflammation: Central to MS and present in AD
• Mitochondrial Dysfunction: Seen in both diseases
• Blood-Brain Barrier: Impaired in both conditions

This creates a strong rationale for testing DMF in AD.

Trial Design

Study Design

This is a randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial:

• Allocation: 1:1 randomization to DMF or placebo
• Blinding: Double-blind (participants and investigators)
• Duration: 48 weeks (12 months)
• Setting: Single center (Medical University of Lodz, Poland)

Treatment Regimen

The dosing follows the approved MS regimen with adaptation:

Dimethyl Fumarate Arm:

• Starting dose: 120 mg twice daily for 4 weeks (titration)
• Maintenance: 240 mg twice daily
• Total daily dose: 480 mg

• Matching tablets, same titration schedule

Inclusion Criteria

• Age 50-85 years
• Diagnosis of probable Alzheimer's disease per NIA-AA criteria
• MMSE score 18-26 (mild-to-moderate disease)
• Amyloid positive (confirmed by PET or CSF biomarkers)
• Stable on allowed AD medications (if applicable) for ≥8 weeks
• Caregiver available to supervise treatment and attend assessments

Exclusion Criteria

• Diagnosis of other dementia types (vascular, Lewy body, frontotemporal)
• Significant psychiatric illness (depression, schizophrenia)
• History of stroke or significant cerebrovascular disease
• Current participation in other clinical trials
• Prior DMF exposure
• Contraindications to MRI
• Liver disease, significant renal disease
• Pregnancy or breastfeeding

Randomization and Stratification

Participants may be stratified by:

• Disease severity (MMSE 18-22 vs. 23-26)
• Concomitant AD medication use (yes/no)

Endpoints

Primary Endpoints

• Timeframe: Baseline to Week 48
• ADAS-Cog is the gold standard for measuring cognitive function in AD trials
• 11-item version ranges from 0-70, higher scores indicate worse function
• Mean decline in placebo is approximately 4-6 points over 12 months

• Adverse events (AEs), serious adverse events (SAEs)
• Laboratory abnormalities (hematology, chemistry)
• Discontinuation rates

Secondary Endpoints

• Aβ42 (amyloid)
• Total tau (neurodegeneration)
• Phosphorylated tau p-tau181 (tau pathology)
• Nrf2 pathway activation markers (HO-1, NQO1)

• Hippocampal volume change
• Whole brain volume change
• Ventricular enlargement

• ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living)
• Clinical Dementia Rating Sum of Boxes (CDR-SB)

• Peripheral blood mononuclear cell (PBMC) Nrf2 activity
• Plasma HO-1, NQO1 levels

Exploratory Endpoints

• Neuropsychiatric symptoms (NPI)
• Quality of life measures
• Pharmacokinetic sampling

Background and Preclinical Data

Clinical Evidence from Multiple Sclerosis

DMF has been used in over 500,000 MS patients worldwide, providing extensive safety data:

Common Adverse Events:

• Flushing (32-40%)
• Gastrointestinal symptoms (nausea, diarrhea, abdominal pain) (20-30%)
• Lymphopenia (2-5%)
• Headache (10-15%)

• Progressive multifocal leukoencephalopathy (PML): ~1/100,000
• Severe liver injury: Rare
• Gastrointestinal serious events: Rare

• Up to 13 years of follow-up data
• No increased malignancy risk
• Manageable laboratory abnormalities

Preclinical Data in AD Models

Multiple studies have evaluated DMF in AD models:

APP/PS1 Transgenic Mice:

• DMF treatment improved spatial memory in Morris water maze
• Reduced amyloid plaque burden in cortex and hippocampus
• Decreased inflammatory markers (IL-1β, TNF-α)
• Enhanced Nrf2 nuclear translocation in brain
• Improved mitochondrial function

• Reduced cognitive deficits on multiple behavioral tests
• Decreased tau phosphorylation
• Reduced microglial activation
• Enhanced antioxidant enzyme expression

• Protected neurons against Aβ-induced toxicity
• Reduced oxidative stress markers
• Inhibited inflammation in glial cells
• Enhanced autophagy

Human Data Supporting Nrf2 Activation

Biomarker studies in MS patients demonstrate Nrf2 pathway activation:

• Increased HO-1 expression in immune cells
• Elevated NQO1 activity
• Reduced oxidative stress markers
• Anti-inflammatory effects on cytokine profile

Cross-Linking

Related Mechanisms

• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Oxidative stress in Alzheimer's](/mechanisms/oxidative-stress-alzheimers)
• [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Nrf2 signaling pathway](/mechanisms/nrf2-signaling-pathway)

Related Proteins/Genes

• [NFE2L2](/genes/nfe2l2) (Nrf2 gene)
• [KEAP1](/genes/keap1)
• [HO-1](/genes/hmox1) (Heme oxygenase-1)
• [NQO1](/genes/nqo1)

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)

Related Therapeutics

• [Nrf2-activating therapies](/therapeutics/nrf2-activating-therapies)
• [Antioxidant therapies](/therapeutics/antioxidant-therapies-neurodegeneration)
• [Drug repurposing in neurodegeneration](/therapeutics/drug-repurposing-neurodegeneration)

Challenges and Considerations

Dose Translation from MS to AD

The MS dose (240 mg twice daily) was selected for:

• Balance of efficacy and gastrointestinal tolerability
• Optimal Nrf2 activation in peripheral immune cells

• CNS penetration may be more important than peripheral effects
• Higher doses might be needed for CNS target engagement
• Different side effect profile in elderly population

Disease Stage Considerations

Optimal benefit may be achieved in earlier disease stages:

• Mild cognitive impairment (MCI) due to AD
• Early AD (MMSE 24-30)
• Pre-symptomatic individuals with genetic risk

Combination Therapy Potential

DMF may be combined with:

• Approved AD therapies (cholinesterase inhibitors, memantine)
• Anti-amyloid antibodies (lecanemab, donanemab)
• Anti-tau therapies

Biomarker Validation

Validating Nrf2 activation in AD brain is challenging:

• CSF Nrf2 pathway markers may not reflect brain effects
• PET tracers for Nrf2 are not available
• Post-mortem studies require drug discontinuation

Current Status and Future Directions

Trial Status

As of 2026, this trial is:

• Status: Active, recruiting
• Location: Medical University of Lodz, Poland
• Enrollment: 30 participants

• Safety of DMF in AD population
• Cognitive outcomes (ADAS-Cog change)
• Biomarker changes (CSF, MRI)
• Nrf2 pathway engagement

Implications of Positive Results

If the trial demonstrates:

• Favorable safety
• Slower cognitive decline
• Biomarker evidence of Nrf2 activation
• Reduced neurodegeneration on MRI

• Advancement to larger Phase 3 trials
• Development of Nrf2-activating drugs specifically for AD
• Combination approaches with other AD therapies

Implications of Negative Results

Negative results would:

• Challenge the Nrf2 activation hypothesis in AD
• Suggest need for higher doses or different agents
• Require biomarker optimization for future trials

Conclusion

This Phase 2 trial represents an important test of the Nrf2 activation hypothesis in Alzheimer's disease. By repurposing dimethyl fumarate—a drug with established safety in MS—researchers can efficiently evaluate whether enhancing antioxidant and anti-inflammatory pathways provides cognitive benefit in AD.

The 48-week design allows detection of clinically meaningful cognitive effects while maintaining reasonable trial duration. The inclusion of biomarker endpoints provides insights into mechanism engagement, enabling interpretation of positive or negative results.

Success would validate Nrf2 as a therapeutic target in AD and potentially provide a new disease-modifying treatment approach. Even if results are negative, the trial provides valuable data about antioxidant strategies in neurodegeneration.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06850597 |
| Phase | Phase 2 |
| Status | Active, recruiting |
| Sponsor | Medical University of Lodz (Poland) |
| Enrollment | 30 participants |
| Intervention | Dimethyl fumarate (oral) |
| Comparator | Placebo |
| Duration | 48 weeks |
| Location | Medical University of Lodz, Poland |
| Design | Randomized, double-blind, placebo-controlled |

The Nrf2 Pathway in Alzheimer's Disease

Nrf2 Biology

The Nrf2 (Nuclear factor erythroid 2-related factor 2) transcription factor is the master regulator of cellular antioxidant response. Under normal conditions, Nrf2 is bound to Keap1 (Kelch-like ECH-associated protein 1) in the cytoplasm, which keeps it inactive and promotes its degradation. When cells encounter oxidative stress, Nrf2 is released from Keap1, translocates to the nucleus, and binds to the Antioxidant Response Element (ARE) in DNA, triggering transcription of a battery of protective genes[@cuadrado2022].

Key Nrf2 target genes include:

• Heme oxygenase-1 (HO-1) - degrades heme, producing neuroprotective biliverdin
• NAD(P)H quinone dehydrogenase 1 (NQO1) - neutralizes quinones
• Glutamate-cysteine ligase (GCL) - rate-limiting step in glutathione synthesis
• Superoxide dismutase (SOD) - converts superoxide to hydrogen peroxide
• Glutathione peroxidases - reduce peroxides
• Thioredoxin - maintains cellular redox balance

Nrf2 Dysfunction in AD

The Nrf2 pathway is dysfunctional in Alzheimer's disease at multiple levels:

Animal studies demonstrate that Nrf2 deficiency accelerates Alzheimer's-like pathology, while Nrf2 activation is protective[@itoh2015]. This makes the Nrf2 pathway an attractive therapeutic target.

Post-Mortem Evidence

Human post-mortem studies provide strong evidence for Nrf2 pathway dysfunction in AD[@cruz2023]:

• Reduced Nrf2 nuclear localization in AD frontal cortex
• Decreased expression of Nrf2 target genes (HO-1, NQO1, GCL)
• Increased Keap1 expression, sequestering more Nrf2
• Oxidative damage markers inversely correlate with Nrf2 activity

Mechanism of Action

DMF-Mediated Nrf2 Activation

Dimethyl fumarate exerts its neuroprotective effects primarily through Nrf2 pathway activation[@pomyt2023]:

DMF → Covalent modification of Keap1 cysteine residues → Nrf2 release → Nuclear translocation → ARE binding → Antioxidant gene expression

Key steps in the mechanism:

Pharmacokinetics and CNS Penetration

DMF undergoes rapid metabolism to monomethyl fumarate (MMF), the active metabolite, which is responsible for Nrf2 activation[@lin2024]:

• Oral bioavailability: ~54%
• Peak plasma concentration: 2-3 hours post-dose
• MMF CSF penetration: Demonstrated in human studies
• Dose proportionality: Linear PK up to 240 mg

Neuroprotective Mechanisms in AD

The Nrf2 pathway addresses multiple AD pathological features:

1. Oxidative Stress Reduction

AD brains exhibit some of the highest levels of oxidative damage in any neurological condition:

• Elevated lipid peroxidation (4-hydroxynonenal, malondialdehyde)
• Protein oxidation (carbonylated proteins)
• DNA oxidation (8-hydroxyguanosine)
• Decreased glutathione levels
• Impaired mitochondrial function

2. Neuroinflammation Modulation

Nrf2 activation has profound anti-inflammatory effects:

• Suppresses pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6)
• Inhibits microglial activation
• Reduces nitric oxide production
• Modulates NLRP3 inflammasome activity

3. Amyloid-Beta Modulation

Preclinical evidence suggests DMF may affect amyloid pathology:

• Reduced Aβ toxicity in neuronal cultures
• Decreased amyloid plaque burden in APP/PS1 mice
• Improved synaptic function in amyloid-bearing neurons
• Enhanced amyloid clearance mechanisms

4. Tau Pathology Protection

Nrf2 activation may protect against tau pathology:

• Reduced tau phosphorylation in model systems
• Protection against tau-induced mitochondrial dysfunction
• Preservation of microtubule integrity

5. Mitochondrial Protection

Nrf2 target genes protect mitochondrial function:

• Enhanced electron transport chain efficiency
• Reduced mitochondrial ROS production
• Improved ATP production
• Protection against mitochondrial permeability transition

Additional DMF Mechanisms

Beyond Nrf2, DMF has additional mechanisms:

• Immunomodulation: Shifts toward anti-inflammatory T-cell phenotypes
• Hydroxycarboxylic acid receptor 2 (HCA2) activation: Contributes to anti-inflammatory effects
• Gap junction modulation: May protect neuronal connectivity

Study Design

Patient Population

Inclusion Criteria

• Diagnosis: Probable Alzheimer's disease (NIA-AA criteria)
• Disease Stage: Mild-to-moderate
• Age: 50-85 years
• MMSE Score: 18-26
• Amyloid Status: Confirmed positive via PET or CSF biomarkers (Aβ42/Aβ40 ratio or p-tau181)
• Stable Medications: No changes to AD medications for 8 weeks prior
• Caregiver: Available for study participation

Exclusion Criteria

• Significant cerebrovascular disease
• Psychiatric conditions precluding participation
• Active infections
• Immunosuppressive therapy
• History of gastrointestinal intolerance to DMF
• Significant liver or kidney disease

Treatment Arms

| Arm | Intervention | Dose | Duration |
|-----|--------------|------|----------|
| Active | Dimethyl fumarate | Titration to 240 mg BID | 48 weeks |
| Placebo | Matching placebo | N/A | 48 weeks |

Titration Schedule (typical for DMF):

• Week 1-2: 120 mg once daily
• Week 3-4: 120 mg twice daily
• Week 5+: 240 mg twice daily

Endpoints

Primary Endpoints

Secondary Endpoints

Rationale for Repurposing

Established Safety Profile

Dimethyl fumarate (Tecfidera) has been FDA-approved for relapsing-remitting multiple sclerosis since 2013, with extensive clinical experience:

• >500,000 patients treated worldwide
• Long-term safety data up to 10+ years
• Well-characterized adverse effect profile
• Established CNS penetration
• Proven anti-inflammatory effects in humans[@dmflon2023]

Known Side Effect Profile

Common DMF side effects (usually transient):

• Flushing (most common, 30-40%)
• Gastrointestinal (nausea, diarrhea, abdominal pain) - 20-30%
• Headache - 10-15%
• Fatigue - 10%

AD-Specific Rationale

Alzheimer's disease brains show specific features that make DMF an attractive candidate:

| AD Pathology | Nrf2 Pathway Effect |
|--------------|-------------------|
| Chronic oxidative stress | Direct antioxidant enzyme upregulation |
| Neuroinflammation | Suppress pro-inflammatory cytokines |
| Mitochondrial dysfunction | Protect electron transport chain |
| Synaptic loss | Preserve synaptic protein expression |
| Amyloid toxicity | Reduce Aβ-induced oxidative damage |

Preclinical Evidence

Animal Model Studies

Multiple preclinical studies support DMF's potential in AD[@chen2023]:

• APP/PS1 mice: DMF treatment reduced cognitive deficits in Morris water maze
• 5xFAD mice: Decreased amyloid plaque burden and neuroinflammation
• Tau transgenic models: Reduced tau pathology and improved behavior
• Oxidative stress models: Protected against ROS-induced neuronal death

Mechanistic Studies

• In vitro: DMF protected neurons from Aβ-induced toxicity
• Microglial cultures: Suppressed LPS-induced inflammatory activation
• Astrocyte cultures: Enhanced Nrf2-dependent antioxidant production

Comparison to Other Nrf2 Activators

DMF is one of several Nrf2-activating approaches being explored in AD[@yang2024]:

| Compound | Mechanism | Development Stage |
|----------|-----------|-----------------|
| Dimethyl fumarate | Keap1 modification | Phase 2 |
| Bardoxolone methyl | Nrf2 activation via Keap1 | Phase 2 |
| Sulforaphane | Nrf2 activation via Michael addition | Phase 1 |
| CDDO-Me | Nrf2 activation | Preclinical |

Clinical Significance

Advancing Nrf2-Targeted Therapy

This trial represents a critical step in validating Nrf2 activation as a therapeutic strategy in AD:

Comparison to Other Approaches

| Approach | Target | Current Status | Limitation |
|----------|--------|---------------|------------|
| Anti-amyloid antibodies | Amyloid plaques | Approved (lecanemab, donanemab) | Limited efficacy, brain edema risk |
| Cholinesterase inhibitors | Symptoms | Generic available | Symptomatic only |
| NMDAR antagonist | Symptoms | Generic available | Symptomatic only |
| Nrf2 activators (DMF) | Oxidative stress/neuroinflammation | Phase 2 | Unproven in AD |

Broader Implications

If successful, this trial would:

• Validate oxidative stress as a therapeutic target
• Support testing other Nrf2 activators in AD
• Establish biomarkers for Nrf2 pathway engagement
• Enable combination therapy approaches

Challenges and Considerations

Scientific Uncertainties

Practical Considerations

• Flushing and GI side effects may affect adherence
• Placebo response in cognitive outcomes
• Biomarker variability between patients

Related Pages

Mechanisms

• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Oxidative stress in Alzheimer's](/mechanisms/oxidative-stress-alzheimers)
• [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Nrf2 signaling pathway](/mechanisms/nrf2-signaling-pathway)

Proteins and Genes

• [NFE2L2 (Nrf2 gene)](/./genes/nfe2l2)
• [KEAP1](/./genes/keap1)
• [HO-1 (Heme oxygenase-1)](/./genes/hmox1)

Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)

Therapeutics

• [Drug Repurposing in Neurodegeneration](/therapeutics/drug-repurposing-neurodegeneration)
• [Nrf2 Activators](/therapeutics/nrf2-activators)

External Links

• [ClinicalTrials.gov - NCT06850597](https://clinicaltrials.gov/study/NCT06850597)
• [Medical University of Lodz](https://umed.pl)
• [PubMed - Nrf2 and Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/?term=Nrf2+Alzheimer)
• [PubMed - Dimethyl fumarate neuroprotection](https://pubmed.ncbi.nlm.nih.gov/?term=dimethyl+fumarate+Alzheimer)

References

See Also

Related Hypotheses:

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypotheses/h-7bb47d7a)
• [Microbial Inflammasome Priming Prevention](/hypotheses/h-e7e1f943)
• [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypotheses/h-82922df8)

• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's](/analysis/SDA-2026-04-01-gap-20260401-225155)

• [Macroautophagy Dysfunction in PD - Experiment Design](/experiment/exp-wiki-experiments-macroautophagy-dysfunction-parkinsons)
• [Cytochrome Therapeutics](/experiment/exp-wiki-experiments-lipid-droplet-lysosome-axis-parkinsons)
• [Neural Stem Cell Therapy for Alzheimer's Disease](/experiment/exp-wiki-experiments-neural-stem-cell-therapy-alzheimers-disease)